ArticleFrontiers in immunology2022
C-reactive protein isoforms as prognostic markers of COVID-19 severity.
Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 27 citations in OpenAlex.
- The prognostic value of red cell distribution width-to-albumin ratio (RAR) in COVID-19 pneumonia: implications for early diagnosis.Virology journal · 2026Article
- Euthyroid Sick Syndrome as an Index of Prognosis in Severe COVID-19 Disease.Medicina (Kaunas, Lithuania) · 2025Article
- C-reactive protein conformations and their association with the IL-1β/IL-6 pathway in ocular inflammatory conditions.Frontiers in immunology · 2025Article
- Redefining CRP in tissue injury and repair: more than an acute pro-inflammatory mediator.Frontiers in immunology · 2025Review
- Development of a Model for Predicting Mortality Among Patients Hospitalized with COVID-19 During Their Stay in a Clinical Centre.Journal of clinical medicine · 2024Article
- High myoglobin level as an independent risk factor for death in elderly patients with critical COVID-19 infection: a retrospective case-control study.BMC infectious diseases · 2024Article
- Article
- Higher monomeric C-reactive protein levels are associated with premature coronary artery disease.Frontiers in immunology · 2024Article
- C-reactive protein-complement factor H axis as a biomarker of activity in early and intermediate age-related macular degeneration.Frontiers in immunology · 2024Observational
- Effects of C-reactive protein trajectories of critically ill patients with sepsis on in-hospital mortality rate.Scientific reports · 2023Review
- Observational
- Pentameric C-reactive protein is a better prognostic biomarker and remains elevated for longer than monomeric CRP in hospitalized patients with COVID-19.Frontiers in immunology · 2023Article
- Monomeric C-reactive protein as a biomarker for major depressive disorder.Frontiers in psychiatry · 2023Review
- Serum CRP interacts with SPARC and regulate immune response in severe cases of COVID-19 infection.Frontiers in immunology · 2023Article
Corrections and comments
- Erratum issued
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
C-reactive protein (CRP), an active regulator of the innate immune system, has been related to COVID-19 severity. CRP is a dynamic protein undergoing conformational changes upon activation in inflammatory microenvironments between pentameric and monomeric isoforms. Although pentameric CRP is the circulating isoform routinely tested for clinical purposes, monomeric CRP shows more proinflammatory properties. Therefore, we aimed to determine the potential of monomeric CRP in serum as a biomarker of disease severity in COVID-19 patients (admission to intensive care unit [ICU] and/or in-hospital mortality). We retrospectively determined clinical and biological features as well as pentameric and monomeric CRP levels in a cohort of 97 COVID-19 patients within 72h of hospital admission. Patients with severe disease had higher levels of both pentameric and monomeric CRP. However, multivariate analysis showed increased mCRP but not pCRP to be independently associated to disease severity. Notably, mCRP levels higher than 4000 ng/mL (OR: 4.551, 95% CI: 1.329-15.58), together with number of co-morbidities, low lymphocyte count, and procalcitonin levels were independent predictors of disease severity in the multivariate model. Our results show the potential of mCRP levels as a marker of clinical severity in COVID-19 disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.